Skip to main content
37°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Personalis, Inc.
< Previous
1
2
3
4
Next >
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
April 05, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
March 22, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
March 07, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Appoints Christopher Hall as Chief Executive Officer
March 02, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
February 09, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate at Upcoming Investor Conferences
February 06, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
February 03, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
MRNA
PSNL
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
January 04, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces CEO Retirement and Transition
December 14, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Cancer Assay NeXT Personal Ranks #1 on The Scientist’s Top 10 Innovations of 2022
December 12, 2022
From
Personalis, Inc.
Via
Business Wire
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
November 30, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
November 21, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Third Quarter 2022 Financial Results
November 02, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
October 31, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Third Quarter 2022 Financial Results
October 19, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
October 04, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
August 30, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
August 17, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
August 15, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
August 04, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Second Quarter 2022 Financial Results
August 03, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
August 02, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Second Quarter 2022 Financial Results
July 20, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
July 12, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports First Quarter 2022 Financial Results
May 04, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at Upcoming Investor Conferences
April 28, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.